Shares of Opiant Pharmaceuticals fell in trading after the company announced that the Phase II trial evaluating a naloxone nasal spray for the treatment of bulimia nervosa failed to meet primary endpoints and will discontinue the program.
A U.S. FDA advisory panel voted in favor of J&J’s experimental nasal spray esketamine, which has a compound similar to often-abused ketamine, bringing the drug closer to approval.
Dr. Reddy’s Laboratories Ltd. and its subsidiary, Promius Pharma LLC, announced the approval of Tosymra (previously known as DFN-02) by the U.S. Food and Drug Administration.
Britain’s Consort Medical Plc agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc.
Janssen, part of Johnson & Johnson, announced results from two long-term Phase III trials of esketamine nasal spray in patients with treatment-resistant depression.
Janssen Pharmaceuticals is eying a potential breakthrough in treating refractory major depressive disorder.
Optinose announced that the U.S. FDA approved the company’s New Drug Application for XHANCE for treating nasal polyps in patients 18 years of age and older.
During its second-quarter 2017 financial reporting, Egalet Corporation also announced it plans to cut the company’s non-sales staff by almost 40 percent.
Germany-based Fresenius Kabi, part of Fresenius SE & Co. KGaA, slapped down $4.3 billion to acquire Illinois-based Akorn Inc. and a larger toehold in the United States.
Amphastar Pharmaceuticals Inc. said the U.S. Food and Drug Administration had rejected its application to market an intranasal version of the emergency opioid-overdose treatment, naloxone.